In 2008, Thorsten Hagemann and colleagues demonstrated that the depletion of IKK-β activity within TAMs can revert their tumor-promoting phenotype to antitumor M1 phenotype, indicating that reprogramming TAMs by target IKK-β target to eliminate tumor cells (44). Here, IKBKB is linked to neoplasm.